Press Releases
  Date Title View
Aug 27, 2010
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a ...
PDF
Aug 18, 2010
WALTHAM, Mass., Aug 18, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops ...
PDF
Aug 4, 2010
WALTHAM, Mass., Aug 04, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops t...
PDF
Jul 29, 2010
WALTHAM, Mass., Jul 29, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN) an...
PDF
Jul 28, 2010
WALTHAM, Mass., Jul 28, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc. (NASDAQ:IMGN), a biotechnology company that develops targeted anticancer products, today announced that the Company will host a conference call at 4:30 p.m. ET on Wednesday, August 4, 2010, to discuss ImmunoGen's financial results for the three...
PDF
Jul 7, 2010
PDF
Jun 24, 2010
WALTHAM, Mass., Jun 24, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that sanofi-aventis has initiated a Phase I clinical trial with SAR650984, an investigational antibody that targets cancer cells ...
PDF
Jun 22, 2010
WALTHAM, Mass., Jun 22, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the promotion to vice president of two executive directors - Godfrey Amphlett, Ph.D., and Robert J. Lutz, Ph.D. - who have played central roles in establishing ImmunoGen's high...
PDF
Jun 7, 2010
WALTHAM, MA, June 7, 2010 – ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of the first clinical data for the Company’s IMGN388 anticancer compound at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in ...
PDF
Jun 5, 2010
WALTHAM, Mass., Jun 05, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of clinical data from a Phase Ib/II trial conducted by Roche and Genentech to investigate the safety and preliminary efficacy of trastuzumab-DM1 (T-DM1) used i...
PDF
Jun 3, 2010
WALTHAM, Mass., Jun 03, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN) announced today that Daniel Junius, President and CEO, will present at two investor conferences next week. These presentations will be webcast live and can be accessed through the "Investor Information" section of the Company's website, www.immunogen.com. An archive of...
PDF
May 24, 2010
WALTHAM, Mass., May 24, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that there will be several clinical data presentations for compounds utilizing the Company's Targeted Antibody Payload (TAP) technology at the 2...
PDF
May 10, 2010
WALTHAM, Mass., May 10, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase 1,350,000 shares of common stock at a public o...
PDF
May 7, 2010
WALTHAM, Mass., May 07, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN) is scheduled to present at the Bank of America Merrill Lynch Health Care Conference at 1:40 pm ET on May 13, 2010. The Conference is being held at the Grand Hyatt New York. ImmunoGen's presentation will be webcast live and can be...
PDF
May 6, 2010
WALTHAM, Mass., May 06, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that it has priced a public offering of 9,000,000 shares of its common stock at a price of $8.00 per share. Net proceeds, after underwriting discounts and commissions and expen...
PDF
May 5, 2010
WALTHAM, Mass., May 05, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that it intends to offer, subject to market and other conditions, 8,500,000 shares of its common stock in an underwritten public offering. ImmunoGen ...
PDF
Apr 29, 2010
WALTHAM, Mass., Apr 29, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended March 31, 2010 - the third quarter of the Company's 2010 ...
PDF
Apr 22, 2010
WALTHAM, Mass., Apr 22, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products, today announced that will host a conference call at 4:30 pm ET on Thursday, April 29, 2010 to discuss the Company's financial results for the three-month period ended March 31, 2010 - the third quarter...
PDF
Apr 15, 2010
WALTHAM, Mass., Apr 15, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that Roche has provided a favorable update related to its plans to apply for marketing approval of trastuzumab-DM1 (T-DM1) in the US. T-DM1 comprises ImmunoGen's DM1 cancer-ce...
PDF
Mar 18, 2010
WALTHAM, Mass., Mar 18, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN) is scheduled to present at the 2010 Barclays Capital Global Healthcare Conference at 3:45 pm ET on March 24, 2010. The Conference is being held at the Loews Miami Beach Hotel in Miami Beach, Florida. ImmunoGen's presentation wil...
PDF
FirstPrevious ...
13
NextLast

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue